GRFSGrifols SA

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Raimon G. Roura

Location

New York, USA

Exchange

Nasdaq

Website

https://grifols.com

Summary

Grifols, S.

Company Info

CEO

Raimon G. Roura

Location

New York, USA

Exchange

Nasdaq

Website

https://grifols.com

Summary

Grifols, S.

AI Insights for GRFS
5 min read

Quick Summary

Grifols S.A. is a global healthcare and biopharmaceutical company focused mainly on plasma-derived medicines, diagnostics, hospital pharmacy solutions, and bio supplies. The company procures plasma, manufactures therapeutic proteins, and sells products used to treat immune deficiencies, bleeding disorders, liver disease, shock, and other serious medical conditions. Its main product families include immunoglobulins, albumin, alpha-1 antitrypsin, clotting factors, hyperimmune globulins, blood-screening tools, and surgical hemostasis products. Grifols’ customers include hospitals, specialty pharmacies, blood banks, plasma centers, laboratories, government health systems, clinicians, and distributors serving patients with chronic or acute conditions. The company operates in the pharmaceutical products industry and has a large global workforce of about 26,300 employees, with reported operating revenue of about $8.81 billion and net income of about $586.8 million in the provided period.

Strengths

•

Grifols’ primary strength is its established position in plasma-derived therapeutics, a specialized market with high regulatory barriers and complex manufacturing requirements.

•

The company has a broad product portfolio that includes immunoglobulins, albumin, alpha-1 antitrypsin, clotting factors, hyperimmune globulins, diagnostics, and surgical sealants.

•

Its revenue base is large, with reported operating revenue of about $8.81 billion, and it has a workforce of roughly 26,300 employees supporting global operations.

•

Demand for many of its therapies is medically necessary and often recurring, which can provide more durable revenue than discretionary healthcare products.

•

The company also benefits from exposure to growing markets such as autoimmune disease treatment, immunohematology diagnostics, blood safety, surgical bleeding control, and plasma protein therapeutics.

Key Risks

•

Grifols faces significant legal, regulatory, financial, and reputational risks.

•

The dispute with Gotham City Research could continue to weigh on investor confidence, especially if questions around leverage, EBITDA, debt, or related-party structures remain unresolved.

•

High debt perception can increase equity volatility, raise refinancing concerns, and limit strategic flexibility even when operating performance is positive.

•

Plasma collection risk is also important because public opposition to paid plasma models, such as the protest in Ontario, could affect supply agreements, political support, and expansion plans.

What to Watch

During the most recent referenced period, Grifols reported substantial operating revenue of about $8.81 billion, gross profit of about $3.36 billion, operating income of about $1.45 billion, and net income of about $586.8 million.
The company remained profitable, with basic EPS of $0.26 and a reported earnings yield above 10%, which suggests the market is pricing in meaningful risk despite positive earnings.
A key event in the recent news flow was Grifols’ decision to sue Gotham City Research after a critical report contributed to a sharp market-value decline.
The company publicly denied the allegations, while Spain’s regulator defended the existence of audited accounts, helping shares rebound after a severe selloff.
Another important operational event was FDA approval of Grifols’ fibrin sealant for pediatric surgical bleeding control, which expands the clinical utility of VISTASEAL in the United States and Canada.

Price Drivers

•

Grifols’ stock price is likely driven by earnings quality, debt perception, plasma-product demand, regulatory news, and investor confidence in reported leverage and EBITDA.

•

The company’s valuation metrics appear relatively low, with a price-to-earnings ratio around 9.55, an earnings yield around 10.47%, and EV/EBITDA near 6.71 based on the provided data.

•

Those figures can attract value-oriented investors if they trust the accounting, cash flow, and debt trajectory.

•

At the same time, the Gotham City Research controversy is a major sentiment driver because the report questioned debt, EBITDA, leverage, and related-party issues tied to Scranton Enterprises, even though Grifols denied the allegations and planned legal action.

•

The 52-week range of $6.86 to $9.62, beta of 1.132, and recent trading volume above its moving average indicate that the stock may be sensitive to both company-specific headlines and broader healthcare risk appetite.

Recent News

•

Recent news highlighted Grifols’ plan to sue Gotham City Research after a critical report erased roughly $2.5 billion from the company’s market value.

•

Grifols denied the allegations, which focused on debt, EBITDA, leverage, and ties to Scranton Enterprises, and the company said it would seek damages.

•

The shares rebounded after a 26% plunge, helped in part by Spain’s regulator defending Grifols’ audited accounts.

•

Another recent item noted FDA approval of Grifols’ fibrin sealant, VISTASEAL in the United States and Canada, for pediatric surgical bleeding control, supported by strong phase 3b trial efficacy and safety data.

•

The news feed also included public opposition to paid plasma collection in Ontario, where union members criticized a long-term arrangement involving Canadian Blood Services and Grifols.

Market Trends

•

Broader market trends are generally supportive for Grifols because demand for plasma-derived therapies continues to rise globally.

•

The plasma protein therapeutics market is projected to grow as autoimmune disorders, immune deficiencies, critical-care needs, and product innovation increase demand for immunoglobulin, albumin, and related therapies.

•

The immunohematology market is also expected to grow, supported by safer transfusion practices, automation, PCR and molecular diagnostics, AI, and stronger blood-safety programs.

•

The autoimmune disease diagnostics market is forecast to expand at an 8.3% CAGR from 2025 to 2031, which may benefit companies with laboratory and diagnostic exposure such as Grifols.

•

At the same time, the industry faces pressure from high manufacturing costs, plasma supply constraints, regulatory scrutiny, reimbursement negotiations, and increasing competition from both large biopharma companies and specialized biologics firms.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on GRFS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show